PMID

Data

Article Title

Organization

Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.

Celera

Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.

Celera

Efforts toward oral bioavailability in factor VIIa inhibitors.

Celera

Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.

Celera

Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth.

Celera

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease.

Celera

Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.

Celera

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.

Celera

2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.

Celera

Factor VIIa inhibitors: gaining selectivity within the trypsin family.

Celera

Novel 5-azaindole factor VIIa inhibitors.

Celera

Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

Celera

Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.

Celera

Structure-guided design of peptide-based tryptase inhibitors.

Celera

Discovery of novel heterocyclic factor VIIa inhibitors.

Celera